首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >The macrolide-lincosamide-streptogramin B resistance phenotypes characterized by using a specifically deleted antibiotic-sensitive strain of Streptomyces lividans.
【2h】

The macrolide-lincosamide-streptogramin B resistance phenotypes characterized by using a specifically deleted antibiotic-sensitive strain of Streptomyces lividans.

机译:大环内酯-林可酰胺-链霉菌素B耐药表型的特征是使用特异删除的对抗生素敏感的淡紫色链霉菌菌株。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Genes conferring resistance to macrolide, lincosamide, and streptogramin B (MLS) antibiotics via ribosomal modification are widespread in bacteria, including clinical isolates and MLS-producing actinomycetes. Such erm-type genes encode enzymes that mono- or dimethylate residue A-2058 of 23S rRNA. The different phenotypes resulting from monomethylation (MLS-I phenotype, conferred by erm type I genes) or dimethylation (MLS-II phenotype due to erm type II genes) have been characterized by introducing tlrD or ermE, respectively, into an MLS-sensitive derivative of Streptomyces lividans TK21. This strain (designated OS456) was generated by specific replacement of the endogenous resistance genes lrm and mgt. The MLS-I phenotype is characterized by high-level resistance to lincomycin with only marginal resistance to macrolides such as chalcomycin or tylosin, whereas the MLS-II phenotype involves high-level resistance to all MLS drugs. Mono- and dimethylated ribosomes were introduced into a cell-free protein-synthesizing system prepared from S. lividans and compared with unmodified particles in their response to antibiotics. There was no simple correlation between the relative potencies of MLS drugs at the level of the target site (i.e., the ribosome) and their antibacterial activities expressed as MICs.
机译:通过核糖体修饰赋予大环内酯,林可酰胺和链霉菌素B(MLS)抗生素耐药性的基因广泛存在于细菌中,包括临床分离株和产生MLS的放线菌。此类erm型基因编码的酶具有23S rRNA单或二甲基化残基A-2058。通过将tlrD或ermE分别引入MLS敏感的衍生物中来表征由单甲基化(MLS-I表型,由erm I型基因赋予)或二甲基化(MLS-II表型由于erm II型基因而产生)的不同表型。链霉菌TK21。该菌株(命名为OS456)是通过内源抗性基因lrm和mgt的特异性置换而产生的。 MLS-I表型的特征在于对林可霉素的高水平抗性,而对大环内酯类如查尔霉素或泰乐菌素仅具有少量抗性,而MLS-II表型涉及对所有MLS药物的高水平抗性。将单和二甲基化的核糖体引入由利维链球菌制备的无细胞蛋白质合成系统中,并将其与未修饰的颗粒对抗生素的反应进行比较。 MLS药物在靶位点(即核糖体)水平上的相对效力与其以MIC表示的抗菌活性之间没有简单的相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号